Physician profile
Robert B Hightower
NPI 1861425878
$8,166.16
in general payments reported to CMS, 2019-2025
50 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $552 · 2021: $677 · 2022: $1,810 · 2023: $1,468 · 2024: $1,443 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,432.36 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,015.60 | 2021-2025 | |
| Glaxosmithkline, LLC. | $830.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $448.11 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $388.71 | 2019-2025 | |
| Novo Nordisk INC | $310.17 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.25 | 2019-2024 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $242.70 | 2019-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $220.85 | 2023-2025 | Gemtesa |
| Mylan Specialty L.P. | $211.54 | 2020-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.80 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $200.52 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $187.98 | 2019-2025 | Vaxelis, Capvaxive, Vaxneuvance |
| Axsome Therapeutics, INC. | $179.15 | 2024-2025 | Auvelity, Symbravo |
| Lundbeck LLC | $174.43 | 2023-2025 | Rexulti |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $173.36 | 2019-2022 | |
| Amgen INC. | $158.35 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $144.67 | 2019 | |
| Sunovion Pharmaceuticals INC. | $133.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.78 | 2021-2025 | Glassia |
| Viatris Specialty LLC | $95.92 | 2025 | Yupelri |
| Corium, LLC | $90.95 | 2022-2023 | Azstarys, Adlarity, Adlarity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $88.05 | 2022-2025 | Caplyta |
| Insulet Corporation | $76.22 | 2025 | Omnipod |
| Astellas Pharma US INC | $76.11 | 2019-2025 | Veozah |
| Alkermes, INC. | $68.33 | 2020-2024 | Vivitrol |
| Biogen, INC. | $65.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $56.74 | 2023-2024 | Qelbree, Qelbree |
| Jazz Pharmaceuticals INC. | $43.86 | 2022 | |
| Phathom Pharmaceuticals, INC. | $43.14 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $39.11 | 2024 | |
| Bausch Health US, LLC | $37.65 | 2025 | Aplenzin, Wellbutrin |
| Lexicon Pharmaceuticals, INC. | $35.83 | 2023 | Inpefa |
| Dexcom, INC. | $33.25 | 2021-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $32.50 | 2023 | Xyosted, Nocdurna, Tlando |
| Genentech USA, INC. | $32.14 | 2021 | |
| Medtronic, INC. | $26.50 | 2023 | Intellis Adaptivestim |
| Abbott Laboratories | $26.26 | 2021-2022 | |
| Boston Scientific Corporation | $19.79 | 2025 | Wavewriter Alpha Prime 16 |
| Grifols USA, LLC | $19.68 | 2019 | |
| Exact Sciences Corporation | $19.43 | 2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $17.03 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $16.20 | 2023 | Quviviq |
| Verona Pharma, INC. | $16.19 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $13.71 | 2024 | Uzedy |
| Sanofi Pasteur INC. | $13.15 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.86 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $11.40 | 2019 | |
| Eisai INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.